Literature DB >> 8704178

Activation of naive and memory T cells by interleukin-15.

H Kanegane1, G Tosato.   

Abstract

Interleukin-15 (IL-15), a product of monocytes and other cells, has biological activities similar to those of IL-2, including growth stimulation of activated T cells, induction of cytolytic effector cells, and B-cell costimulation for proliferation and lg production. We report that IL-15 at optimal concentrations rapidly induced memory (CD45RO+) CD4+ and CD8+ T cells and naive (CD45RO-) CD8+ T cells to express the CD69 activation marker followed by proliferation. By contrast, IL-15 failed to induce naive (CD45RO-) CD4+ T cells to express CD69 or to proliferate. Similar findings were obtained with IL-2. Unlike the other T-cell subsets, CD4+ T cells with a naive phenotype expressed little or no IL-2R beta chain, a shared component of the IL-2 and IL-15 receptors required for receptor function. A monoclonal antibody to the IL-2R beta chain, Mik beta 1, reduced CD69 expression and proliferation in CD4+ memory, CD8+ memory, and CD8+ naive T cells activated by IL-15. These results confirm the biological similarities of IL-2 and IL-15. They further document that the pool of naive CD4+ cells, unlike the pool of memory CD4+, memory CD8+, and naive CD8+ cells, is not regulated directly by the T-cell growth factors IL-2 or IL-15.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8704178

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  Utilizing IL-12, IL-15 and IL-7 as Mucosal Vaccine Adjuvants.

Authors:  Liljana Stevceva; Marcin Moniuszko; Maria Grazia Ferrari
Journal:  Lett Drug Des Discov       Date:  2006       Impact factor: 1.150

Review 2.  Lung transplantation: infection, inflammation, and the microbiome.

Authors:  Takeshi Nakajima; Vyachesav Palchevsky; David L Perkins; John A Belperio; Patricia W Finn
Journal:  Semin Immunopathol       Date:  2011-01-27       Impact factor: 9.623

Review 3.  Interleukin-15 biology and its therapeutic implications in cancer.

Authors:  Jason C Steel; Thomas A Waldmann; John C Morris
Journal:  Trends Pharmacol Sci       Date:  2011-10-25       Impact factor: 14.819

4.  Activation, survival and apoptosis of CD45RO+ and CD45RO- T cells of human immunodeficiency virus-infected individuals: effects of interleukin-15 and comparison with interleukin-2.

Authors:  H Naora; M Gougeon
Journal:  Immunology       Date:  1999-06       Impact factor: 7.397

5.  Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal.

Authors:  David L Tamang; Doug Redelman; Bryce N Alves; Leanne Vollger; Christy Bethley; Dorothy Hudig
Journal:  Cytokine       Date:  2006-12-22       Impact factor: 3.861

6.  Effect of IL15 on T cell clonality in vitro and in the synovial fluid of patients with rheumatoid arthritis.

Authors:  K Masuko-Hongo; M Kurokawa; T Kobata; K Nishioka; T Kato
Journal:  Ann Rheum Dis       Date:  2000-09       Impact factor: 19.103

7.  IL-7- and IL-15-mediated TCR sensitization enables T cell responses to self-antigens.

Authors:  Pratima Deshpande; Mary M Cavanagh; Sabine Le Saux; Karnail Singh; Cornelia M Weyand; Jörg J Goronzy
Journal:  J Immunol       Date:  2013-01-16       Impact factor: 5.422

Review 8.  Receptor-directed therapy of T-cell leukemias and lymphomas.

Authors:  John C Morris; Thomas A Waldmann; John E Janik
Journal:  J Immunotoxicol       Date:  2008-04       Impact factor: 3.000

Review 9.  Antibody-based therapy of leukaemia.

Authors:  John C Morris; Thomas A Waldmann
Journal:  Expert Rev Mol Med       Date:  2009-09-30       Impact factor: 5.600

10.  IL-15 treatment during acute simian immunodeficiency virus (SIV) infection increases viral set point and accelerates disease progression despite the induction of stronger SIV-specific CD8+ T cell responses.

Authors:  Yvonne M Mueller; Duc H Do; Susan R Altork; Carol M Artlett; Edward J Gracely; Christos D Katsetos; Agustin Legido; Francois Villinger; John D Altman; Charles R Brown; Mark G Lewis; Peter D Katsikis
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.